A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

ClinicalTrials.gov ID: NCT07755410

Public ClinicalTrials.gov record NCT07755410. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 12, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared to Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.

Study identification

NCT ID: NCT07755410
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Alkermes, Inc.; Industry
Enrollment: 312 participants

Conditions and interventions

Conditions

Attention Deficit Disorder With Hyperactivity (ADHD)

Interventions

ALKS 7290 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 10, 2026 (Actual)
Primary completion: Jul 2027 (Estimated)
Completion: Jul 2027 (Estimated)
Last update posted: Oct 7, 2026

2026 – 2027

United States locations

U.S. sites: 19
U.S. states: 10
U.S. cities: 16

Facility	City	State	ZIP	Site status
Alkermes Investigational Site	Little Rock	Arkansas	72211	Recruiting
Alkermes Investigational Site	Chino	California	91710	Recruiting
Alkermes Investigator Site	Chino	California	91710	Recruiting
Alkermes Investigational Site	Clermont	Florida	34711	Recruiting
Alkermes Investigational Site	Jacksonville	Florida	32256	Recruiting
Alkermes Investigational Site	Lakeland	Florida	33803	Recruiting
Alkermes Investigational Site	Largo	Florida	33777	Recruiting
Alkermes Investigational Site	Maitland	Florida	32751	Recruiting
Alkermes Investigator Site	Maitland	Florida	32751	Recruiting
Alkermes Investigational Site	Maitland	Florida	98007	Recruiting
Alkermes Investigational Site	Orlando	Florida	32801	Recruiting
Alkermes Investigational Site	Tampa	Florida	33634	Recruiting
Alkermes Investigational Site	Decatur	Georgia	30030	Recruiting
Alkermes Investigational Site	Memphis	Michigan	38119	Recruiting
Alkermes Investigational Site	North Canton	Ohio	44720	Recruiting
Alkermes Investigational Site	East Providence	Rhode Island	02914	Recruiting
Alkermes Investigational Site	North Charleston	South Carolina	29405	Recruiting
Alkermes Investigational Site	Austin	Texas	78759	Recruiting
Alkermes Investigational Site	Bellevue	Washington	98007	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07755410, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 7, 2026 · Synced Oct 12, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07755410 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →